检索结果-南通市图书馆

维普期刊数据库博看期刊

在线全文

学校读者我要写书评

暂无评论

输尿管原发滤泡性淋巴瘤1例

肿瘤研究与临床 2024年第2期36卷 132-135页

作者：叶振邦吴杰邱田郭蕾王冰凝农琳寿建忠黄文亭郑闪国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院病理科北京100021 国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院泌尿外科北京100021

目的探讨原发于输尿管的滤泡性淋巴瘤(FL)的病理诊断及鉴别诊断要点。方法回顾性分析中国医学科学院肿瘤医院2023年6月收治的1例输尿管原发FL患者的临床病理资料,并复习相关文献。结果患者为老年男性,因体检发现左侧输尿管中上段占位半... 详细信息

目的探讨原发于输尿管的滤泡性淋巴瘤(FL)的病理诊断及鉴别诊断要点。方法回顾性分析中国医学科学院肿瘤医院2023年6月收治的1例输尿管原发FL患者的临床病理资料,并复习相关文献。结果患者为老年男性,因体检发现左侧输尿管中上段占位半个月就诊。既往有尿路结石病史。因术前影像资料难以明确诊断而行左肾及输尿管全长膀胱部分切除术。镜下形态学与结内滤泡淋巴瘤相同,表现为排列紧密的淋巴滤泡,生发中心极向消失,肿瘤细胞以中心细胞为主,可见散在分布的中心母细胞,未见星空现象;免疫表型示B细胞标志阳性,表达CD10、bcl-6及bcl-2,CD21和CD23显示滤泡树突细胞网存在;抗原受体基因克隆性重排聚合酶链反应显示有B细胞受体克隆性重排;荧光原位杂交显示存在bcl-2基因易位。术后PET-CT检查未发现其他病灶,支持输尿管原发FL诊断。术后行膀胱灌注治疗、局部放疗。结论输尿管原发FL临床表现无特异性,与输尿管癌在影像学上不能鉴别。肿瘤的形态学观察辅以免疫表型、抗原受体基因克隆性重排及荧光原位杂交检测可明确诊断。需行全身检查除外系统性FL累及输尿管可能。

关键词：淋巴瘤,滤泡性输尿管原位杂交,荧光抗原受体基因克隆性重排免疫表型

聚焦2019年欧洲泌尿外科学会年会肾癌研究进展及带来的思考

在线全文

学校读者我要写书评

暂无评论

中华泌尿外科杂志 2019年第5期40卷 321-324页

作者：寿建忠国家癌症中心/北京协和医学院中国医学科学院肿瘤医院泌尿外科北京100021

作为欧洲泌尿外科学会(EAU)规模最大、最具影响力的科学盛会——第34届EAU年会已经圆满落下帷幕.大会期间所公布的全部研究数据、指南更新乃至争议都一如既往地在全球泌尿外科医生的心中激起层层涟漪.其中在肾癌领域,本次年会共收录相... 详细信息

作为欧洲泌尿外科学会(EAU)规模最大、最具影响力的科学盛会——第34届EAU年会已经圆满落下帷幕.大会期间所公布的全部研究数据、指南更新乃至争议都一如既往地在全球泌尿外科医生的心中激起层层涟漪.其中在肾癌领域,本次年会共收录相关研究超过百篇,几乎囊括肾癌诊疗的全部热点,特别是在某些研究领域带来了理念上的冲击,产生了深远的甚至是里程碑式的影响,必将指引未来肾癌研究与治疗的方向。

关键词：泌尿外科学会肾癌年会欧洲聚焦外科医生 EAU

3D magnetic field guided sunflower-like nanocatalytic active swarm targeting patients-derived organoids

在线全文

学校读者我要写书评

暂无评论

Nano Research 2023年第1期16卷 1021-1032页

作者： Dong Liu Ruirui Guo Shuangshuang Mao Yanjie Huang Bin Wang Zijian Wu Xuanjie Xia Jian Dong Yu Xin Ruiyang Xie jianzhong shou Wei Sun Yuan Pang Yuan Lu Key Laboratory of Industrial Biocatalysis Ministry of EducationDepartment of Chemical EngineeringTsinghua UniversityBeijing 100084China Tianjin Industrial Microbiology Key Laboratory College of BiotechnologyTianjin University of Science and TechnologyTianjin 300457China Biomanufacturing Center Department of Mechanical EngineeringTsinghua UniversityBeijing 100084China Department of Neurosurgery Beijing Tiantan HospitalCapital Medical UniversityBeijing 100070China National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Biomanufacturing Center Dept.of Mechanical EngineeringTsinghua UniversityBeijing 100084China

Nanocatalytic medicine triggering in situ catalytic reactions has been considered as a promising strategy for tumor-selective ***,the targeted distribution of nanocatalysts was still low,considering the absence of targeting propulsion ***,encouraged by the fast-developing controllable microrobotics for targeting delivery,a sunflower-like nanocatalytic active swarm(SNCAS)controlled by a three-dimensional(3D)magnetic field was proposed for synergistic tumorselective and magnetic-actively tumor-targeting ***,a patient-derived renal cancer cell 3D organoid was utilized for the verification of the effective tumor therapeutic *** the targeted control of 3D magnetic field,the multiple cascade catalytic efficiency of SNCAS based on Fenton reaction was evaluated,resulting in efficient tumor cell apoptosis and *** the patient-derived organoid treatment,the SNCAS presented significant lethality toward 3D organoid structure to induce cell apoptosis with the collapse of organoid *** targeting efficiency was further enhanced under the magnetic-controllable of ***,empowered by the magnetic control technology,the synergistic therapeutic strategy based on controllable swarm combined active targeting and tumor-specific catalytic nanomedicine has provided a novel way for advanced cancer ***,3D patient-derived organoids were proved as a powerful tool for the effectiveness verification of nanocatalytic medicine.

关键词： nanocatalytic swarm magnetic control patients-derived organoids

Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors:A systematic review and network meta-analysis

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Innovation 2022年第4期1卷 293-304页

作者： Ruiyang Xie Jie Wu Bingqing Shang Xingang Bi Chuanzhen Cao Youyan Guan Hongzhe Shi jianzhong shou Department of Urology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Background:By prolonging overall survival and reducing disease recurrence rates,immune checkpoint inhibitors(ICIs)are an emerging adjuvant therapy option for patients with resectable malignant ***,the safety profile(deaths and adverse events[AEs])of adjuvant ICIs has not been fully ***:We searched the literature for phase III randomized clinical trials that compared PD-1,PD-L1,and CTLA-4 inhibitors in solid malignant *** of death,discontinuation,AEs of any cause,treatment-related adverse events(TRAEs),and immune-related adverse events(IRAEs)were extracted for the network *** meta-analyses with low incidence and poor convergence are reported as incidences with 95%confidence intervals(95%CIs).Results:Ten randomized clinical trials that included 9243 patients who received ICI adjuvant therapy were *** total,21 deaths due to TRAEs were recorded,with an overall incidence of 0.40%(95%CI:0.26–0.61).The treatment-related mortality rates for ipilimumab(0.76%,95%CI:0.31–1.55)and atezolizumab(0.56%,95%CI:0.18–1.31)were higher than for pembrolizumab(0.24%,95%CI:0.10–0.56)and nivolumab(0.30%,95%CI:0.08–0.77).The most frequent causes of death were associated with the gastrointestinal(0.10%,95%CI:0.04–0.24)and pulmonary(0.08%,95%CI:0.03–0.21)*** with the control arm,we found that nivolumab(odds ratio[OR]:2.73,95%CI:0.49–15.85)and atezolizumab(OR:12.43,95%CI:2.42–78.48)caused the fewest grade≥3 TRAEs and *** reported IRAEs of special interest were analyzed,and two agents were found to have IRAEs with incidences>10%,i.e.,hepatitis for atezolizumab(14.80%,95%CI:12.53–17.32)and hypophysitis for ipilimumab(13.53%,95%CI:11.38–15.90).Conclusions:Ipilimumab and atezolizumab were correlated with higher treatment-related death rates than pembrolizumab and nivolumab,in which the gastrointestinal and pulmonary systems were mostly *** severe TRAEs and IRAEs,nivolumab and atezolizumab are lik

关键词： immune checkpoint inhibitor adjuvant therapy cancer adverse event death

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

前列腺重复穿刺研究进展

中华泌尿外科杂志 2021年第1期42卷 71-74页

作者：胡林军寿建忠北京市朝阳区桓兴肿瘤医院泌尿外科 100122 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院泌尿外科北京100006

前列腺穿刺存在漏诊前列腺癌的可能,重复穿刺有其必要性。本文对前列腺重复穿刺独立危险因素、穿刺途径选择和穿刺新技术进展方面进行综述,以提高临床医生对前列腺重复穿刺适应证的认识。对符合前列腺重复穿刺的患者,推荐使用mpMRI靶向... 详细信息

前列腺穿刺存在漏诊前列腺癌的可能,重复穿刺有其必要性。本文对前列腺重复穿刺独立危险因素、穿刺途径选择和穿刺新技术进展方面进行综述,以提高临床医生对前列腺重复穿刺适应证的认识。对符合前列腺重复穿刺的患者,推荐使用mpMRI靶向穿刺,以提高有临床意义前列腺癌的检出率,减少无临床意义前列腺癌的检出率。

关键词：前列腺肿瘤重复穿刺研究进展

在线全文

学校读者我要写书评

暂无评论

溶瘤病毒在膀胱癌治疗中的研究现状与进展

中华泌尿外科杂志 2020年第8期41卷 633-636页

作者：尚冰清寿建忠国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院泌尿外科北京100021

膀胱癌是泌尿系统最常见的恶性肿瘤。免疫治疗作为一种新型的治疗方法,在尿路上皮癌领域取得了巨大成功。溶瘤病毒作为免疫治疗的一项新兴研究热点,可以通过特异性破坏肿瘤细胞或激活特异性抗肿瘤免疫的双重作用机制来达到抗肿瘤效应。... 详细信息

膀胱癌是泌尿系统最常见的恶性肿瘤。免疫治疗作为一种新型的治疗方法,在尿路上皮癌领域取得了巨大成功。溶瘤病毒作为免疫治疗的一项新兴研究热点,可以通过特异性破坏肿瘤细胞或激活特异性抗肿瘤免疫的双重作用机制来达到抗肿瘤效应。目前,溶瘤病毒在膀胱癌的治疗中取得了重大突破,特别是在非肌层浸润性膀胱尿路上皮癌的治疗方面。包括腺病毒、柯萨奇病毒、牛痘病毒及单纯疱疹病毒等在内的溶瘤病毒,在膀胱灌注治疗膀胱癌的多项临床试验中显示出良好的安全性和有效性。特别是在重组腺病毒干扰素α治疗膀胱癌的Ⅲ期临床试验中,高达53%的患者3个月时获得完全缓解,且无Ⅳ/Ⅴ级不良反应。本文就溶瘤病毒在膀胱癌治疗中的研究现状和进展进行综述。

关键词：膀胱肿瘤膀胱癌溶瘤病毒膀胱灌注

中性粒细胞在肾癌发生发展中的作用及其研究现状

在线全文

学校读者我要写书评

暂无评论

中华泌尿外科杂志 2021年第8期42卷 637-640页

作者：谢睿扬寿建忠国家癌症中心/国家肿瘤临床医学中心/中国医学科学院北京协和医学院肿瘤医院泌尿外科北京100021

肾细胞癌是泌尿系统的常见恶性肿瘤。中性粒细胞所属的免疫微环境对肾癌进展有抑制和促进发展双重作用,其通过介导炎症反应、表达趋化因子、生成中性粒细胞外诱捕网等机制产生的促癌作用已成为研究热点。靶向药物、免疫检查点抑制剂作... 详细信息

肾细胞癌是泌尿系统的常见恶性肿瘤。中性粒细胞所属的免疫微环境对肾癌进展有抑制和促进发展双重作用,其通过介导炎症反应、表达趋化因子、生成中性粒细胞外诱捕网等机制产生的促癌作用已成为研究热点。靶向药物、免疫检查点抑制剂作为晚期肾癌患者的全身系统治疗,其疗效和预后均与中性粒细胞活跃存在相关性,肿瘤组织中性粒细胞浸润、外周血中性粒细胞水平增高提示肾癌患者的不良预后。中性粒细胞表型与功能可受到肾癌相关炎症影响,通过高表达CXC趋化因子导致肾癌不良预后。此外,中性粒细胞外诱捕网可捕获血液中肿瘤细胞,协助其生存与迁移。

关键词：癌肾细胞中性粒细胞中性粒细胞外诱捕网药物治疗

局限性高危前列腺癌综合诊治一例报告并治疗决策综合分析

在线全文

学校读者我要写书评

暂无评论

中华泌尿外科杂志 2017年第6期38卷 461-468页

作者：温力寿建忠国家癌症中心、中国医学科学院北京协和医学院肿瘤医院泌尿外科北京100021

目的探讨前列腺癌不同治疗手段的选择和时机。方法回顾性分析1例局限性高危前列腺癌患者的完整临床资料。患者69岁，因尿频伴排尿困难2年入院。直肠指检：前列腺2。增大，右侧叶质地硬，近前列腺尖部可触及0．8cm结节。血清T—PSA36．8n... 详细信息

目的探讨前列腺癌不同治疗手段的选择和时机。方法回顾性分析1例局限性高危前列腺癌患者的完整临床资料。患者69岁，因尿频伴排尿困难2年入院。直肠指检：前列腺2。增大，右侧叶质地硬，近前列腺尖部可触及0．8cm结节。血清T—PSA36．8ng/ml。前列腺穿刺活检：右侧叶5针，4／5见癌组织，Gleason评分7分（4＋3）。临床分期：T2bN0M0。结果患者先后接受根治性前列腺切除术、挽救性放疗＋内分泌治疗、阿比特龙、恩杂鲁胺、镭一223临床试验、多西他赛＋泼尼松化疗以及米托蒽醌＋泼尼松化疗，几乎涵盖了目前国内所有的治疗手段。患者从初始治疗到死亡历经57个月。结论对于高危前列腺癌患者，尤其是高龄患者首先推荐根治性放疗＋2～3年的内分泌治疗；对于年轻患者采用根治性前列腺切除＋扩大淋巴结清扫术的多模式治疗是一种肯定的选择。根治性前列腺切除术后伴有高危因素或已出现复发的患者进行术后放疗，能降低生化复发率和提高局部控制率。阿比特龙、恩杂鲁胺和多西他赛＋泼尼松化疗之间顺序的选择，目前还基于患者自身情况、既往治疗史、有无症状以及不良反应等综合考虑决定。

关键词：前列腺癌局限性高危多模式治疗放疗

Machine learning-based prognostic and metastasis models of kidney cancer

在线全文

学校读者我要写书评

暂无评论

Cancer Innovation 2022年第2期1卷 124-134页

作者： Yuxiang Zhang Na Hong Sida Huang Jie Wu Jianwei Gao Zheng Xu Fubo Zhang Shaohui Ma Ye Liu Peiyuan Sun Yanping Tang Chun Liu jianzhong shou Meng Chen National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Digital Health China Technologies Co.Ltd.BeijingChina Department of public policy Cornell UniversityIthacaNew YorkUSA The Key Laboratory of Geriatrics Beijing Institute of GeriatricsInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijing Hospital/National Center of Gerontology of National Health CommissionBeijingChina

Background:Kidney cancer originates from the urinary tubule epithelial system of the renal parenchyma,accounting for 20% of all urinary system *** 70% of cases are localized at diagnosis,and 30%are *** localized kidney cancers can be cured by surgery,but most metastatic patients relapse after surgery and eventually die of kidney ***,accurately predicting patient survival and identifying high-risk metastatic patients will effectively guide interventions and improve ***:This study used the data of 12,394 kidney cancer patients from the surveillance,epidemiology,and end results database to construct a research cohort related to kidney cancer survival and *** machine learning models(including support vector machines,logistic regression,decision tree,random forest,XGBoost,AdaBoost,K-nearest neighbors,and multilayer perceptron)were developed to predict the survival and metastasis of kidney cancer and six evaluation indicators(accuracy,precision,sensitivity,specificity,F1 score,and area under the receiver operating characteristic[AUROC])were used to verify,evaluate,and optimize the ***:Among the eight machine learning models,Logistic Regression has the highest AUROC in both prediction *** 3-year survival prediction,the Logistic Regression model had an accuracy of 0.684,a sensitivity of 0.702,a specificity of 0.670,a precision of 0.686,an F1 score of 0.683,and an AUROC of *** tumor metastasis prediction,the Logistic Regression model had an accuracy of 0.800,a sensitivity of 0.540,a specificity of 0.830,a precision of 0.769,an F1 score of 0.772,and an AUROC of ***:In this study,we selected appropriate variables from both statistical and clinical significance and developed and compared eight machine learning models for predicting 3-year survival and metastasis of kidney *** prediction results and evaluation results demonstrated that our model could provide decis

关键词： machine learning kidney cancer survival metastasis prognostic model